December 18, 2009–Diagnostic Nano Technology Corporation (DNA), a subsidiary of Avisio, Inc., says that with the early laboratory success of its Instant Detect Technology in the detection of certain viruses that cause Dengue Fever, it plans to begin testing the nanotechnology on the detection of the H1N1 virus.

Instant Detect is a portable nano-based technology that operates in the field and provides immediately-available results that do not require the expertise of a specialized lab technician to read. The technology is expected to be used by individuals in the health care and agricultural industries to detect disease-causing pathogens that can impact global food supplies and human health.

"Ongoing testing of this type is a necessary component in the process of selecting DNA’s initial human application development projects," says Amro Albanna, CEO of DNA and Avisio, Inc. "We are cautiously optimistic about the market opportunity that exists for DNA’s Instant Detect product, especially with regard to potential human applications. We realize that we are early in the process and still have a number of milestones to reach, including but not limited to further proof of concept, the ability to produce product at scale, third-party validation and regulatory approvals, before we can begin to market a product."